Tables, Figures, and Listings
Mock Shells for Clinical Study Report

Study Title: A Phase II Study of Treatment Z in Patients with Cardiovascular Disease
Protocol Number: GHI-469
Sponsor: Global Health Partners
Date: 06 June 2025

Table of Contents

1.0 TABLES
Table 14.1.1: Demographics and Baseline Characteristics	Page 4
Table 14.1.2: Medical History	Page 5
Table 14.1.3: Demographics by Subgroup (Age, Sex, Race)	Page 6
Table 14.1.4: Prior and Concomitant Medications	Page 7
Table 14.2.1: Primary Efficacy Analysis - Change from Baseline at Week 12	Page 8
Table 14.2.2: Secondary Efficacy Analysis - Key Secondary Endpoints	Page 9
Table 14.2.3: Time-to-Event Analysis - Kaplan-Meier Estimates	Page 10
Table 14.2.4: Binary Endpoint Analysis	Page 11
Table 14.2.5: Subgroup Analysis of Primary Endpoint	Page 12
Table 14.3.1: Treatment-Emergent Adverse Events	Page 13
Table 14.3.2: Laboratory Test Results - Hematology	Page 14
Table 14.3.3: Laboratory Test Results - Chemistry	Page 15
Table 14.3.4: Vital Signs Summary	Page 16
Table 14.3.5: Shift Table for Laboratory Parameters	Page 17

2.0 FIGURES
Figure 14.2.1: Primary Endpoint Over Time (Line Plot)	Page 18
Figure 14.2.2: Subgroup Analysis of Primary Endpoint (Forest Plot)	Page 19
Figure 14.2.3: Kaplan-Meier Plot of Time to Event	Page 20
Figure 14.2.4: Box Plots of Primary Endpoint by Visit	Page 21
Figure 14.3.1: Adverse Events by System Organ Class (Bar Chart)	Page 22
Figure 14.3.2: Correlation of Primary Endpoint with Key Biomarker (Scatter Plot)	Page 23

3.0 LISTINGS
Listing 16.2.1: Patient Disposition	Page 24
Listing 16.2.2: Protocol Deviations	Page 25
Listing 16.2.3: Patients Excluded from Analysis	Page 26
Listing 16.2.4: Demographic Data	Page 27
Listing 16.2.5: Concomitant Medications	Page 28
Listing 16.2.6: Individual Efficacy Response Data	Page 29
Listing 16.2.7: Adverse Event Listings (Safety Population)	Page 30
Listing 16.2.8: Individual Laboratory Measurements	Page 31

1.0 TABLES

Table 14.1.1: Demographics and Baseline Characteristics

Characteristic	Statistic	Treatment A
(N=XX)	Treatment B
(N=XX)	Total
(N=XX)	
Age (years)	n				
	Mean (SD)				
	Median				
	Min, Max				
Sex, n (%)					
Male	n (%)				
Female	n (%)				

SD = standard deviation; BMI = body mass index: Percentages are based on the number of patients in the analysis population within each treatment group.

Table 14.1.3: Demographics by Subgroup (Age, Sex, Race)

Subgroup	Statistic	Treatment A
(N=XX)	Treatment B
(N=XX)	
Age < 65 years	n (%)	XX (XX.X%)	XX (XX.X%)	
Age ≥ 65 years	n (%)	XX (XX.X%)	XX (XX.X%)	
Male	n (%)	XX (XX.X%)	XX (XX.X%)	
Female	n (%)	XX (XX.X%)	XX (XX.X%)	
White	n (%)	XX (XX.X%)	XX (XX.X%)	
Black or African American	n (%)	XX (XX.X%)	XX (XX.X%)	
Asian	n (%)	XX (XX.X%)	XX (XX.X%)	
Other	n (%)	XX (XX.X%)	XX (XX.X%)	

Note: Percentages are calculated based on the number of patients in each treatment group.

Table 14.1.4: Prior and Concomitant Medications

ATC Level 2 Classification
Preferred Name	Treatment A
(N=XX)
n (%)	Treatment B
(N=XX)
n (%)	Total
(N=XX)
n (%)	
Analgesics	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
   Acetaminophen	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
   Ibuprofen	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
Antihypertensives	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
   Lisinopril	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	
   Amlodipine	XX (XX.X%)	XX (XX.X%)	XX (XX.X%)	

ATC = Anatomical Therapeutic Chemical Classification System.: Medications were coded using WHO Drug Dictionary. A patient with multiple medications within a category is counted only once in that category.

Table 14.1.2: Medical History

Medical History
System Organ Class
  Preferred Term	Treatment A
(N=XX)
n (%)	Treatment B
(N=XX)
n (%)	Total
(N=XX)
n (%)	
Blood and lymphatic system disorders				
   Anemia				
   Leukopenia				
Cardiac disorders				
   Atrial fibrillation				
   Hypertension				

Note: Medical history was coded using MedDRA version XX.X. A patient with multiple events within a category is counted only once in that category.are calculated based on the number of patients in the safety population.

Table 14.2.1: Primary Efficacy Analysis - Change from Baseline at Week 12 (Full Analysis Set Population)

	 Treatment A
(N=XX)	 Treatment B
(N=XX)	 Difference
(95% CI)	 p-value	
 Primary Endpoint					
 n	 XX	 XX			
 Baseline, Mean (SD)	 XX.X (X.XX)	 XX.X (X.XX)			
 Week 12, Mean (SD)	 XX.X (X.XX)	 XX.X (X.XX)			
 LS Mean (SE)	 XX.X (X.XX)	 XX.X (X.XX)			
 Change from Baseline,
LS Mean (SE)	 XX.X (X.XX)	 XX.X (X.XX)	 X.XX (X.XX, X.XX)	 0.XXX	

CI = confidence interval; SD = standard deviation; SE = standard error; LS = least squares: The primary analysis was based on a mixed model for repeated measures (MMRM) with treatment, visit, and treatment-by-visit interaction as fixed effects, and baseline value as a covariate.

Table 14.2.2: Secondary Efficacy Analysis - Key Secondary Endpoints (Full Analysis Set Population)

Endpoint	 Treatment A
(N=XX)	 Treatment B
(N=XX)	 LS Mean Difference
(95% CI)	 p-value	
 Secondary Endpoint 1					
 n	 XX	 XX			
 LS Mean (SE)	 XX.X (X.XX)	 XX.X (X.XX)	 X.XX (X.XX, X.XX)	 0.XXX	
 ANCOVA p-value				 0.XXX	

 Secondary Endpoint 2					
 n	 XX	 XX			
 LS Mean (SE)	 XX.X (X.XX)	 XX.X (X.XX)	 X.XX (X.XX, X.XX)	 0.XXX	
 ANCOVA p-value				 0.XXX	

CI = confidence interval; SE = standard error; LS = least squares: The analysis was based on an Analysis of Covariance (ANCOVA) model with treatment as fixed effect and baseline value as a covariate.

Table 14.2.3: Time-to-Event Analysis - Kaplan-Meier Estimates (Full Analysis Set Population)

Parameter	 Treatment A
(N=XX)	 Treatment B
(N=XX)	 Hazard Ratio
(95% CI)	 Log-rank
p-value	
 Number of events, n (%)	 XX (XX.X%)	 XX (XX.X%)			
 Censored, n (%)	 XX (XX.X%)	 XX (XX.X%)			
 Median time to event
(95% CI), months	 XX.X
(XX.X, XX.X)	 XX.X
(XX.X, XX.X)			
 6-month event-free rate
(95% CI), %	 XX.X
(XX.X, XX.X)	 XX.X
(XX.X, XX.X)			
 12-month event-free rate
(95% CI), %	 XX.X
(XX.X, XX.X)	 XX.X
(XX.X, XX.X)			
 Hazard ratio (95% CI)			 0.XX (0.XX, 0.XX)	 0.XXX	

CI = confidence interval: Hazard ratio and 95% CI were calculated using a Cox proportional hazards model with treatment as a factor. p-value was calculated using a stratified log-rank test.

Table 14.2.4: Binary Endpoint Analysis (Full Analysis Set Population)

Response Variable	 Treatment A
(N=XX)	 Treatment B
(N=XX)	 Odds Ratio
(95% CI)	 p-value	
 Clinical Response					
 n	 XX	 XX			
 Responders, n (%)	 XX (XX.X%)	 XX (XX.X%)			
 Odds Ratio (95% CI)			 X.XX (X.XX, X.XX)	 0.XXX	

 Complete Response					
 n	 XX	 XX			
 Responders, n (%)	 X (X.X%)	 X (X.X%)			
 Odds Ratio (95% CI)			 X.XX (X.XX, X.XX)	 0.XXX	

CI = confidence interval: Odds ratios, 95% CIs, and p-values were calculated using logistic regression with treatment as the only factor. p-values are based on a two-sided binomial test for difference in proportions.

Table 14.2.5: Subgroup Analysis of Primary Endpoint

Subgroup	Treatment A
(n/N)	Treatment B
(n/N)	Treatment Effect
(95% CI)	p-value for
interaction	
Overall	XX/XX	XX/XX	X.XX (X.XX, X.XX)		
Age				0.XXX	
< 65 years	XX/XX	XX/XX	X.XX (X.XX, X.XX)		
≥ 65 years	XX/XX	XX/XX	X.XX (X.XX, X.XX)		
Sex				0.XXX	
Male	XX/XX	XX/XX	X.XX (X.XX, X.XX)		
Female	XX/XX	XX/XX	X.XX (X.XX, X.XX)		

CI = confidence interval: Treatment effect is expressed as the difference in LS means for continuous endpoints or odds ratio for binary endpoints.

2.0 FIGURES

Figure 14.2.1: Primary Endpoint Over Time (Line Plot)

Line Plot: Primary Endpoint Score Over Time 

Line Graph: Shows trend over time with error bars 
[Treatment A shows improvement compared to Treatment B] 

Note: Error bars represent standard error of the mean. Primary analysis population (N=XXX).

Figure 14.2.2: Subgroup Analysis of Primary Endpoint (Forest Plot)

Forest Plot: Treatment Effect by Subgroup 

Forest Plot: Hazard ratios with confidence intervals 
[Multiple subgroups showing treatment effect] 

Note: Horizontal lines represent 95% confidence intervals. Size of the square is proportional to the number of subjects.

Figure 14.2.3: Kaplan-Meier Plot of Time to Event

Kaplan-Meier Plot: Time to Event 

Kaplan-Meier Curve: Survival probability over time 
[Treatment A shows improved survival vs Treatment B] 

Note: Vertical tick marks indicate censored observations. P-value is from log-rank test.

Figure 14.2.4: Box Plots of Primary Endpoint by Visit

Box Plot: Primary Endpoint by Visit 

Box Plot: Distribution of values by treatment group 
[Shows median, quartiles, and outliers] 

Note: Boxes indicate interquartile range, horizontal line represents median, whiskers extend to min/max values excluding outliers.

Figure 14.3.1: Adverse Events by System Organ Class (Bar Chart)

Bar Chart: Adverse Events by System Organ Class 

Bar Chart: Frequency comparison between groups 
[Compares frequencies across multiple categories] 

Note: GI=Gastrointestinal, CV=Cardiovascular, RS=Respiratory, NS=Nervous System, ME=Metabolism, IN=Infections, SK=Skin disorders.

Figure 14.3.2: Correlation of Primary Endpoint with Key Biomarker (Scatter Plot)

Scatter Plot: Correlation of Primary Endpoint with Biomarker 

Scatter Plot: Correlation between variables 
[Shows positive correlation with regression line] 

Note: Correlation coefficient (r) calculated using Pearson's method. Line represents best linear fit.

3.0 LISTINGS

Listing 16.2.1: Patient Disposition

Study ID	Treatment Group	Patient ID	Randomized	Completed Study	Reason for Discontinuation	
STUDY001	A	SUBJ-1001	Yes	No	Protocol Violation	
STUDY001	B	SUBJ-1002	Yes	Yes		
STUDY001	A	SUBJ-1003	Yes	Yes		
STUDY001	B	SUBJ-1004	Yes	No	Withdrawal by Subject	
STUDY001	A	SUBJ-1005	Yes	Yes		

Note: This listing provides patient disposition information for all randomized patients.

Listing 16.2.2: Protocol Deviations

Study ID	Treatment Group	Patient ID	Date	Description	
STUDY001	A	SUBJ-1001	2023-03-27	Inclusion criteria not met	
STUDY001	B	SUBJ-1003	2023-04-03	Missed assessment	
STUDY001	B	SUBJ-1005	2023-11-10	Inclusion criteria not met	

Note: This listing provides all protocol deviations recorded during the study.

Listing 16.2.3: Patients Excluded from Analysis

Study ID	Treatment Group	Patient ID	Analysis Population	Reason for Exclusion	
STUDY001	A	SUBJ-1020	Per Protocol	Less than 80% treatment compliance	
STUDY001	B	SUBJ-1021	Per Protocol	No post-baseline efficacy measurement	
STUDY001	A	SUBJ-1022	Per Protocol	No post-baseline efficacy measurement	

Note: This listing provides all patients excluded from the Per Protocol analysis population.

Listing 16.2.4: Demographic Data

Study ID	Center	Patient ID	Treatment	Age (years)	Sex	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m²)	
STUDY001	001	SUBJ-1001	A	60	Male	White	Hispanic	189	78	21.8	
STUDY001	001	SUBJ-1002	B	66	Female	Black	Not Hispanic	161	85	32.8	
STUDY001	001	SUBJ-1003	A	62	Male	Asian	Not Hispanic	182	98	29.6	
STUDY001	001	SUBJ-1004	B	53	Female	White	Not Hispanic	160	98	38.3	
STUDY001	001	SUBJ-1005	A	41	Male	Black	Hispanic	169	76	26.6	

BMI = body mass index: This listing provides demographic information for all randomized patients.

Listing 16.2.5: Concomitant Medications

Study ID	Treatment Group	Patient ID	Medication	Indication	Start Date	End Date	Dose/Frequency	
STUDY001	A	SUBJ-1001	Acetaminophen	Headache	2023-02-09	Ongoing	20 mg QD	
STUDY001	B	SUBJ-1002	Ibuprofen	Arthritis	2023-05-13	2023-07-28	1000 mg BID	
STUDY001	B	SUBJ-1003	Lisinopril	Hypertension	2023-06-08	2023-06-02	1000 mg BID	
STUDY001	A	SUBJ-1004	Metformin	Diabetes	2023-05-21	Ongoing	10 mg BID	
STUDY001	B	SUBJ-1005	Atorvastatin	Hypercholesterolemia	2023-03-04	2023-06-15	25 mg QD	
STUDY001	B	SUBJ-1001	Levothyroxine	Hypothyroidism	2023-04-20	2023-10-06	10 mg BID	
STUDY001	A	SUBJ-1002	Amlodipine	Hypertension	2023-02-22	Ongoing	1000 mg BID	

QD = once daily; BID = twice daily: This listing provides all concomitant medications taken during the study period.

Listing 16.2.6: Individual Efficacy Response Data

Study ID	Treatment Group	Patient ID	Visit	Visit Day	Actual Date	Score	Change	
STUDY001	A	SUBJ-1001	Baseline	1	2023-08-29	61	N/A	
STUDY001	A	SUBJ-1001	Week 4	29	2023-01-25	57	-4	
STUDY001	A	SUBJ-1001	Week 8	57	2023-07-11	50	-11	
STUDY001	A	SUBJ-1001	Week 12	85	2023-11-12	44	-17	
STUDY001	A	SUBJ-1001	Week 16	113	2023-12-20	38	-23	
STUDY001	B	SUBJ-1002	Baseline	1	2023-07-29	74	N/A	
STUDY001	B	SUBJ-1002	Week 4	29	2023-05-23	72	-2	
STUDY001	B	SUBJ-1002	Week 8	57	2023-03-12	70	-4	
STUDY001	B	SUBJ-1002	Week 12	85	2023-12-02	67	-7	
STUDY001	B	SUBJ-1002	Week 16	113	2023-11-20	63	-11	
STUDY001	A	SUBJ-1003	Baseline	1	2023-07-29	64	N/A	
STUDY001	A	SUBJ-1003	Week 4	29	2023-03-25	57	-7	
STUDY001	A	SUBJ-1003	Week 8	57	2023-09-14	51	-13	
STUDY001	A	SUBJ-1003	Week 12	85	2023-04-13	46	-18	
STUDY001	A	SUBJ-1003	Week 16	113	2023-04-12	41	-23	
STUDY001	B	SUBJ-1004	Baseline	1	2023-08-14	78	N/A	
STUDY001	B	SUBJ-1004	Week 4	29	2023-07-23	76	-2	
STUDY001	B	SUBJ-1004	Week 8	57	2023-09-18	74	-4	
STUDY001	B	SUBJ-1004	Week 12	85	2023-09-20	71	-7	
STUDY001	B	SUBJ-1004	Week 16	113	2023-08-21	68	-10	

Note: Higher scores indicate worse disease status. Change is from baseline.

Listing 16.2.7: Adverse Event Listings (Safety Population)

Study ID	 Center	 Patient ID	 Treatment	 SOC	 Preferred Term	 Start Date	 End Date	 Ongoing	 Severity	 Serious	 Related	 Action	 Outcome	
 STUDY001	 001	 SUBJ-1001	 A	 GI disorders	 Nausea	 15JAN2025	 	 Yes	 Mild	 Yes	 No	 None	 Ongoing	
 STUDY001	 001	 SUBJ-1002	 B	 Nervous system	 Headache	 15JAN2025	 	 Yes	 Moderate	 No	 Yes	 Dose reduced	 Ongoing	
 STUDY001	 001	 SUBJ-1003	 A	 Nervous system	 Headache	 15JAN2025	 28JAN2025	 No	 Severe	 No	 No	 None	 Recovered	
 STUDY001	 001	 SUBJ-1004	 B	 GI disorders	 Nausea	 15JAN2025	 28JAN2025	 No	 Mild	 No	 Yes	 Dose reduced	 Recovered	
 STUDY001	 001	 SUBJ-1005	 A	 Nervous system	 Headache	 15JAN2025	 	 Yes	 Moderate	 Yes	 No	 None	 Ongoing	

SOC = System Organ Class: Adverse events were coded using MedDRA version XX.X.

Listing 16.2.8: Individual Laboratory Measurements

Study ID	Treatment	Patient ID	Visit	Date	Parameter	Result	Unit	Reference Range	Flag	
STUDY001	A	SUBJ-1001	Screening	2023-01-12	Hemoglobin	13.5	g/dL	13.0-17.0		
STUDY001	A	SUBJ-1001	Screening	2023-01-12	WBC	5.1	10^9/L	4.5-11.0		
STUDY001	A	SUBJ-1001	Screening	2023-01-20	Platelets	225.4	10^9/L	150-450		
STUDY001	A	SUBJ-1001	Screening	2023-01-20	ALT	22	U/L	7-56		
STUDY001	A	SUBJ-1001	Screening	2023-01-05	AST	37	U/L	5-40		
STUDY001	A	SUBJ-1001	Screening	2023-01-24	Creatinine	1.2	mg/dL	0.6-1.2	H	
STUDY001	A	SUBJ-1001	Week 4	2023-03-14	Hemoglobin	14.8	g/dL	13.0-17.0		
STUDY001	A	SUBJ-1001	Week 4	2023-03-19	WBC	5.2	10^9/L	4.5-11.0		
STUDY001	A	SUBJ-1001	Week 4	2023-03-13	Platelets	223.8	10^9/L	150-450		
STUDY001	A	SUBJ-1001	Week 4	2023-03-06	ALT	19	U/L	7-56		
STUDY001	A	SUBJ-1001	Week 4	2023-03-17	AST	39	U/L	5-40		
STUDY001	A	SUBJ-1001	Week 4	2023-03-18	Creatinine	1.0	mg/dL	0.6-1.2		
STUDY001	A	SUBJ-1001	Week 12	2023-05-03	Hemoglobin	13.3	g/dL	13.0-17.0		
STUDY001	A	SUBJ-1001	Week 12	2023-05-14	WBC	5.2	10^9/L	4.5-11.0		
STUDY001	A	SUBJ-1001	Week 12	2023-05-03	Platelets	217.7	10^9/L	150-450		
STUDY001	A	SUBJ-1001	Week 12	2023-05-12	ALT	19	U/L	7-56		
STUDY001	A	SUBJ-1001	Week 12	2023-05-09	AST	34	U/L	5-40		
STUDY001	A	SUBJ-1001	Week 12	2023-05-01	Creatinine	1.2	mg/dL	0.6-1.2	H	
STUDY001	B	SUBJ-1002	Screening	2023-01-13	Hemoglobin	13.7	g/dL	13.0-17.0		
STUDY001	B	SUBJ-1002	Screening	2023-01-19	WBC	5.3	10^9/L	4.5-11.0		
STUDY001	B	SUBJ-1002	Screening	2023-01-21	Platelets	235.1	10^9/L	150-450		
STUDY001	B	SUBJ-1002	Screening	2023-01-03	ALT	22	U/L	7-56		
STUDY001	B	SUBJ-1002	Screening	2023-01-02	AST	39	U/L	5-40		
STUDY001	B	SUBJ-1002	Screening	2023-01-06	Creatinine	1.1	mg/dL	0.6-1.2		
STUDY001	B	SUBJ-1002	Week 4	2023-03-01	Hemoglobin	14.2	g/dL	13.0-17.0		
STUDY001	B	SUBJ-1002	Week 4	2023-03-27	WBC	4.8	10^9/L	4.5-11.0		
STUDY001	B	SUBJ-1002	Week 4	2023-03-08	Platelets	211.1	10^9/L	150-450		
STUDY001	B	SUBJ-1002	Week 4	2023-03-03	ALT	21	U/L	7-56		
STUDY001	B	SUBJ-1002	Week 4	2023-03-14	AST	34	U/L	5-40		
STUDY001	B	SUBJ-1002	Week 4	2023-03-15	Creatinine	1.0	mg/dL	0.6-1.2		
STUDY001	B	SUBJ-1002	Week 12	2023-05-25	Hemoglobin	12.7	g/dL	13.0-17.0	L	
STUDY001	B	SUBJ-1002	Week 12	2023-05-15	WBC	5.2	10^9/L	4.5-11.0		
STUDY001	B	SUBJ-1002	Week 12	2023-05-06	Platelets	246.9	10^9/L	150-450		
STUDY001	B	SUBJ-1002	Week 12	2023-05-08	ALT	21	U/L	7-56		
STUDY001	B	SUBJ-1002	Week 12	2023-05-07	AST	39	U/L	5-40		
STUDY001	B	SUBJ-1002	Week 12	2023-05-04	Creatinine	1.1	mg/dL	0.6-1.2		
STUDY001	A	SUBJ-1003	Screening	2023-01-10	Hemoglobin	12.8	g/dL	13.0-17.0	L	
STUDY001	A	SUBJ-1003	Screening	2023-01-18	WBC	4.6	10^9/L	4.5-11.0		
STUDY001	A	SUBJ-1003	Screening	2023-01-13	Platelets	211.1	10^9/L	150-450		
STUDY001	A	SUBJ-1003	Screening	2023-01-15	ALT	22	U/L	7-56		
STUDY001	A	SUBJ-1003	Screening	2023-01-01	AST	33	U/L	5-40		
STUDY001	A	SUBJ-1003	Screening	2023-01-09	Creatinine	1.2	mg/dL	0.6-1.2		
STUDY001	A	SUBJ-1003	Week 4	2023-03-19	Hemoglobin	13.3	g/dL	13.0-17.0		
STUDY001	A	SUBJ-1003	Week 4	2023-03-23	WBC	5.2	10^9/L	4.5-11.0		
STUDY001	A	SUBJ-1003	Week 4	2023-03-08	Platelets	239.1	10^9/L	150-450		
STUDY001	A	SUBJ-1003	Week 4	2023-03-23	ALT	21	U/L	7-56		
STUDY001	A	SUBJ-1003	Week 4	2023-03-08	AST	40	U/L	5-40	H	
STUDY001	A	SUBJ-1003	Week 4	2023-03-01	Creatinine	1.2	mg/dL	0.6-1.2		
STUDY001	A	SUBJ-1003	Week 12	2023-05-22	Hemoglobin	12.2	g/dL	13.0-17.0	L	
STUDY001	A	SUBJ-1003	Week 12	2023-05-08	WBC	5.0	10^9/L	4.5-11.0		
STUDY001	A	SUBJ-1003	Week 12	2023-05-20	Platelets	251.0	10^9/L	150-450		
STUDY001	A	SUBJ-1003	Week 12	2023-05-23	ALT	22	U/L	7-56		
STUDY001	A	SUBJ-1003	Week 12	2023-05-23	AST	35	U/L	5-40		
STUDY001	A	SUBJ-1003	Week 12	2023-05-28	Creatinine	1.1	mg/dL	0.6-1.2		

WBC = white blood cells; ALT = alanine aminotransferase; AST = aspartate aminotransferase: H = above reference range; L = below reference range: This listing provides individual laboratory test results for all patients.